Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD) (IMPAEPOC)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01266395
First received: December 21, 2010
Last updated: August 8, 2011
Last verified: August 2011

December 21, 2010
August 8, 2011
January 2010
Not Provided
Determine if there are differences in the impact of COPD on patients according to the characteristics of the disease. To measure the impact of specific self-administered questionnaires used in COPD: CDLMQ, GCSQ and CCQ [ Time Frame: Retrospective, (previous 24 months) ] [ Designated as safety issue: No ]
Capacity of Daily Living during the Morning Qustionnaire (CDLMQ), Global Chest Symptoms Questionnaire (GCSQ)and COPD Control Questionnaire (CCQ)
Same as current
Complete list of historical versions of study NCT01266395 on ClinicalTrials.gov Archive Site
Assess comorbidities as a risk factor for frequent exacerbations [ Time Frame: Retrospective, (previous 24 months) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)
Impact of Morning Symptoms in Clinical Control of COPD

Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists. Objective: establish if there are differences in the impact of COPD on daily activities and morning symptoms measured through questionnaires of daily life activity (Capacity of Daily Living during the Morning (CDLM), Global Chest Symptoms Questionnaire (GCSQ))

Not Provided
Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

General Practitioners and pneumologist

COPD
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1268
July 2011
Not Provided

Inclusion Criteria:

  • Patient has signed informed consent form
  • Patients of both sexes,> 40 years.
  • Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:

    • post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) <70%
    • post-bronchodilator FEV1 <80% (stage II, III and IV)

Exclusion Criteria:

  • Participating in an epidemiological study or clinical trial
  • Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
  • Patients with mild COPD: FEV1> 80%
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01266395
NIS-RES-DUM-2010/2
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP